Access cutting-edge neurofibromatosis type 2 treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access neurofibromatosis type 2 specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related neurofibromatosis type 2 treatment provided free
This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.
Sponsor: Recursion Pharmaceuticals Inc.
Check if you qualify for this neurofibromatosis type 2 clinical trial in Washington Dc, DC
If you're searching for neurofibromatosis type 2 treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced neurofibromatosis type 2 specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.